Loading...
01/10 16:14
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
Revenue Third quarter revenue of $137 million increased 23% compared to a year ago, driven by 42% growth in the Pharmacy business and 13% year-over-year growth in the fee-for-service business.
Adjusted EBITDA Adjusted EBITDA loss of $3.5 million in Q3 represents a $4.7 million improvement compared to the same quarter last year.
Capitated Revenue Capitated revenue increased 38.9% year-over-year, contributing to patient services revenue growth.
Pharmacy Revenue Pharmacy revenue was $75.9 million, representing 55.6% of total revenue and increased 57.4% year-over-year due to higher prescription volumes and greater pharmacy attachment within the network.
Gross Profit Gross profit was $18.9 million for the quarter compared to $14.4 million in the third quarter of 2024. Normalized for a $1.8 million reserve adjustment, gross profit would have been $20.7 million.
SG&A Expenses SG&A expenses (excluding depreciation and amortization) were $25.3 million or 18.5% of revenue, down from 26.7% of revenue a year ago, reflecting cost discipline and technology efficiencies.
Cash Flow from Operations Cash flow from operations was negative $27.8 million, improving 9.5% from the prior year, reflecting investments in drug inventory and working capital to support scaling dispensing activity.
Florida Pharmacy Opening: The official opening of the TOI Florida pharmacy location, which will serve network providers requiring delivery of Part B drugs and provide a fast and convenient option for Part B specialty medications for patients and providers.
AI Enablement Efforts: Launched three AI enablement efforts in revenue cycle management, prior authorization services, and patient call center. Transition to agentic AI model expected to reduce submission time from 18 minutes to 5 seconds, saving over 80% per authorization and yielding up to $2 million in operating expense efficiencies.
Expansion in Florida: Expanded partnership with Elevance Health in Florida, doubling Medicare Advantage lives under capitation in less than a year. MSO network in Florida grew to over 200 providers.
Capitation Revenue Growth: New capitation contracts signed across markets in 2025 will contribute an estimated $19 million in full-year revenue, a 29% increase compared to 2024.
MLR Performance: Achieved strong MLR performance on the delegated capitation model in Florida, managing 40,000 lives. Expanded relationship with Elevance Health to include additional Medicare Advantage lives.
Operational Efficiencies: SG&A expenses reduced to 18.5% of revenue, down from 26.7% a year ago, reflecting cost discipline and technology efficiencies.
Value-Based Care Model: Proven ability to manage full delegation with health plan partners, opening new opportunities for value-based contract growth.
Cybersecurity Incident Management: Managed a cybersecurity incident with minimal disruption to operations, ensuring patient treatment plans remained intact and day-to-day operations continued smoothly.
Cybersecurity Incident: A cybersecurity incident at a key vendor disrupted billing and practice management, leading to a temporary inability to bill for fee-for-service claims. This will delay collections into late Q4 and early Q1, potentially impacting cash flow and operational efficiency.
New Capitation Contracts: Margins on new capitation contracts are initially low and will take time to mature, which could impact short-term profitability and financial performance.
Fee-for-Service Revenue: A $1.8 million reserve was recorded against fee-for-service revenue due to potential future bad debt, reflecting caution but also impacting gross profit margins.
Convertible Debt: The company has $86 million in convertible debt maturing in 2027, which could pose financial risks if not managed effectively.
Scaling and Drug Inventory Investments: Negative cash flow from operations, driven by investments in drug inventory and working capital, could strain liquidity as the company scales its dispensing activity.
Revenue Guidance for 2025: The company has raised its full-year revenue guidance for 2025 from $460 million to $480 million to a new range of $495 million to $505 million.
Adjusted EBITDA Guidance for 2025: The company has raised the lower end of its adjusted EBITDA guidance for 2025 from a loss of $17 million to $8 million to a new range of a loss of $13 million to $11 million. This implies adjusted EBITDA between breakeven and positive $2 million for the fourth quarter.
Profitability Expectations: The company expects to achieve adjusted EBITDA profitability in the fourth quarter of 2025 and become free cash flow positive in 2026.
Capitation Revenue Growth: New capitation contracts signed in 2025 are expected to contribute an estimated $19 million in full-year revenue, representing a 29% increase in capitated revenue compared to 2024.
Margins on New Capitation Contracts: Margins on new capitation contracts are expected to mature to target levels over the next few quarters as patients transition to in-network providers and adherence to care pathways improves.
AI Enablement Efforts: The company plans to fully transition its offices and authorizations to an AI model in Q4 2025, reducing submission time from 18 minutes to 5 seconds and delivering over 80% savings per authorization. This initiative is expected to expand to other functions in 2026, potentially yielding $2 million in operating expense efficiencies.
Impact of Cybersecurity Incident: A cybersecurity incident at a key vendor is expected to influence collections in late Q4 2025 and early Q1 2026, but the company projects sufficient cash to meet operating goals for Q4 2025 and 2026.
The selected topic was not discussed during the call.
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
The earnings call reveals strong financial performance with a 44% increase in gross profit and improved EBITDA, indicating operational efficiency. The company has a robust pipeline, especially in fee-for-service revenue, and is on track for cash flow positivity by Q4 2025. Despite some uncertainties in contract terminations, the overall guidance is optimistic, with significant revenue growth expected. The positive sentiment is further supported by improved margins and cost optimization efforts, suggesting a favorable short-term stock price movement.
The earnings call summary indicates strong financial performance with 21% revenue growth, improved gross profit, and reduced losses. New contracts and cost optimization strategies further strengthen the outlook. Although there are some risks in contractual stability and financial performance, management appears confident in their ability to mitigate these. The Q&A section did not reveal significant negative trends. Overall, the positive financial results and guidance, alongside operational improvements and a commitment to shareholder value, suggest a positive stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
